Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study

By Sebastian Martin   Passlick Bernward   Friccius-Quecke Hilke   Jäger Michael   Lindhofer Horst   Kanniess Frank   Wiewrodt Rainer   Thiel Eckhard   Buhl Roland   Schmittel Alexander  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 10, 2007-10 ,pp. : 1637-1644

Springer Publishing Company

Access to resources Recommend Favorite

Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases

By Cimino Ashley  

Breast Cancer Research and Treatment, Vol. 123, Iss. 3, 2010-10 ,pp. : 701-708

Springer Publishing Company

Access to resources Recommend Favorite

Role of the EpCAM (CD326) in prostate cancer metastasis and progression

By Ni Jie  

Cancer and Metastasis Reviews, Vol. 31, Iss. 3-4, 2012-12 ,pp. : 779-791

Springer Publishing Company

Access to resources Recommend Favorite

Exchanging human Fcγ1 with murine Fcγ2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model

By Lutterbuese Petra   Brischwein Klaus   Hofmeister Robert   Crommer Sandrine   Lorenczewski Grit   Petersen Laetitia   Lippold Sandra   Silva Antonio   Locher Mathias   Baeuerle Patrick   Schlereth Bernd  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 4, 2007-04 ,pp. : 459-468

Springer Publishing Company

Access to resources Recommend Favorite

High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer

By Spizzo Gilbert  

Breast Cancer Research and Treatment, Vol. 86, Iss. 3, 2004-08 ,pp. : 207-213

Springer Publishing Company

Access to resources Recommend Favorite